AGENUS Files Routine 8-K on Jan 30; Confirms Nasdaq Listing
Ticker: AGEN · Form: 8-K · Filed: Jan 31, 2024 · CIK: 1098972
Complexity: simple
Sentiment: neutral
Topics: compliance, 8-K, administrative
TL;DR
**AGENUS filed a routine 8-K, no new news, just standard compliance.**
AI Summary
AGENUS INC. filed an 8-K on January 31, 2024, reporting an 'Other Event' that occurred on January 30, 2024. This filing is a routine update to the SEC, confirming the company's current registration details and its listing on The Nasdaq Global Market under the trading symbol AGEN. For investors, this filing primarily serves as a confirmation of the company's ongoing compliance with SEC reporting requirements, indicating no immediate material changes to its operations or financial standing.
Why It Matters
This filing is a standard compliance update, confirming AGENUS INC.'s registration and listing on The Nasdaq Global Market. It signals business as usual, with no new material developments disclosed.
Risk Assessment
Risk Level: low — This 8-K filing is a routine administrative update and does not contain any information that would introduce new risks or change the company's risk profile.
Analyst Insight
A smart investor would recognize this as a routine administrative filing that provides no new material information to act upon. It's a 'no news is good news' scenario, confirming ongoing compliance.
Key Players & Entities
- AGENUS INC. (company) — the registrant filing the 8-K
- The Nasdaq Global Market (company) — the exchange where AGENUS INC.'s common stock is registered
- January 30, 2024 (date) — date of the earliest event reported
- January 31, 2024 (date) — date the 8-K was filed
FAQ
What was the specific 'Item Information' reported in this 8-K filing by AGENUS INC.?
The specific 'Item Information' reported in this 8-K filing by AGENUS INC. was 'Other Events', as stated in the filing.
On what date did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 30, 2024, as indicated by 'Date of Report (Date of earliest event reported): January 30, 2024'.
What is the trading symbol for AGENUS INC. common stock, and on which exchange is it registered?
The trading symbol for AGENUS INC. common stock is AGEN, and it is registered on The Nasdaq Global Market, as stated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the state of incorporation for AGENUS INC.?
AGENUS INC. is incorporated in Delaware, as indicated by 'Delaware (State or Other Jurisdiction of Incorporation)' in the filing.
What is the business address of AGENUS INC. as reported in this filing?
The business address of AGENUS INC. is 3 Forbes Road, Lexington, Massachusetts, 02421, as stated under 'Address of Principal Executive Offices'.
Filing Stats: 397 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2024-01-31 08:00:10
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share AGEN The Nasdaq
- $25 million — nical trial of BMS-986442. The required $25 million payment was received January 30, 2024.
Filing Documents
- agen-20240130.htm (8-K) — 33KB
- 0000950170-24-009147.txt ( ) — 139KB
- agen-20240130.xsd (EX-101.SCH) — 23KB
- agen-20240130_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 11, 2023 Agenus Inc. announced the second development milestone under its global licensing agreement with Bristol Myers Squibb was achieved with the dosing of the first patient in the phase 2 dose expansion portion of the ongoing CA115-001 clinical trial of BMS-986442. The required $25 million payment was received January 30, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 31, 2024 By: /s/ Christine M. Klaskin Christine M. Klaskin, VP Finance